Tacrolimus: In patients with rheumatoid arthritis

Drugs

Volumn 65, Issue 7, 2005, Pages 993-1001

  Curran, Monique P ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BROMOCRIPTINE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; CLOTRIMAZOLE; COLLAGEN; CREATININE; CYTOCHROME P450 3A; DILTIAZEM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ERYTHROMYCIN; ETHINYLESTRADIOL; FK 506 BINDING PROTEIN; FLUCONAZOLE; HEMOGLOBIN A1C; HYPERICUM PERFORATUM EXTRACT; IMIDAZOLE DERIVATIVE; INTERLEUKIN 1BETA; INTERLEUKIN 6; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; NICARDIPINE; NIFEDIPINE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TROLEANDOMYCIN; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ABDOMINAL PAIN; ADJUVANT ARTHRITIS; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; CARTILAGE CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; NAUSEA; NONHUMAN; NORMAL HUMAN; OPEN STUDY; OSTEOBLAST; PANCREATITIS; PHARMACODYNAMICS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TREMOR; VOLUNTEER;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 18644374381     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565070-00005     Document Type: Review

References (33)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46 (2): 328-46
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440
3. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63 (12): 1247-97
4. Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2 (6): 389-406
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43 (10): 623-53
6. Miyata S, Ohkubo Y, Mutoh S. A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res 2005 Jan; 54 (1): 1-9
7. Fujisawa Canada. Prograf® (tacrolimus injection and capsule): product monograph. Markham (ON): Fujisawa Canada, 2004 Feb
8. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989 Jul 15; 143 (2): 718-26
9. Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK506: in vitro effects on the cloned T cell activation. J Immunol 1987 Sep. 15; 139 (6): 1797-803
10. Sakuma S, Kato Y, Nishigaki F, et al. FK506 potently inhibits T cell activation induced TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol 2000 Aug; 130 (7): 165563
11. Sakuma S, Kato Y, Nishigaki F, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol 2001 Apr; (4): 749-57
12. Magari K, Miyata S, Nishigaki F, et al. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthitis. J Rheumatol 2003 Oct; 30 (10): 2193-200
13. Magari K, Nishigaki F, Sasakawa T, et al. Anti-arthritic properties of FK506 on collagen-induced arthritis in rats. Inflamm Res 2003 Dec; 52 (12): 524-9
14. Fuseler JW, Hearth-Holmes M, Grisham MB, et al. FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis. J Rheumatol 2000 Jan; 27 (1): 190-9
15. Sugiyama E, Suzuki H, Tunru IS, et al. FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. J Rheumatol 1994 Sep; 21: 1597-601
16. Inamura N, Hashimoto M Nakahara K, et al. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 1988 Jan; 46 (1): 82-90
17. Takaoka Y, Nagai H, Tanahashi M, et al. Cyclosporin A and FK-506 inhibit development of superantigen-potentiated collagen-induced arthritis in mice. Gen Pharmacol 1998 May; 30 (5): 777-82
18. Sakuma S, Nishigaki F, Magari K, et al. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res 2001 Oct; 50 (10): 509-14
19. Magari K, Miyata S, Nishigaki F, et al. Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res 2004 Oct; 53 (10): 544-50
20. Magari K, Miyata S, Ohkubo Y, et al. Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. Br J Pharmacol 2003 Jul; 139 (5): 927-34
21. Nishigaki F, Sakuma S, Ogawa T, et al. FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur J Pharmacol 2002 Feb 22; 437 (3): 123-8
22. Tang L, Ebara S, Kawasaki S, et al. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol Int 2002; 26 (1): 75-84
23. Voggenreiter G, Assenmacher S, Kreuzfelder E, et al. Immunosuppression with FK506 increases bone induction in demineralized isogeneic and xenogeneic bone matrix in the rat. J Bone Miner Res 2000 Sep; 15 (9): 1825-34
24. Yocum DE, Furst DE, Bensen WG, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford) 2004 Aug; 43 (8): 992-9
25. Kremer JM, Habros JS, Kolba KS, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum 2003 Oct; 48 (10): 2763-8
26. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40 (4): 283-95
27. Fujisawa. Prograf®: prescribing information (US) [online]. Available from URL: http://www.fujisawa.com [Accessed 2003 Aug 10]
28. Holum MB, Wisemandle W, Bekersky I. Concomitant tacrolimus (TAC) and methotrexate (MTX) pharmacokinetics (PK) in rheumatoid arthritis (RA) patients. J Clin Pharmacol 2002 Sep; 42 (9): 1053
29. Kondo H, Abe T, Hashimoto H, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004 Feb; 31 (2): 243-51
30. Furst DE, Saag K, Fleischmann MR, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002 Aug; 46 (8): 2020-8
31. Yocum DE, Furst DE, Kaine JL, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 2003 Dec; 48 (12): 3328-37
32. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 Mar; 31 (3): 315-24
33. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992 May; 35 (5): 498-502